RADIATION THERAPY ONCOLOGY GROUP
RTOG 0126
|
A PHASE III RANDOMIZED STUDY OF HIGH DOSE 3D-CRT
VERSUS STANDARD DOSE 3D-CRT IN PATIENTS TREATED FOR LOCALIZED
PROSTATE CANCER
(Closed to patient accrual as of 8/20/08.)
|
RTOG 0232
|
A PHASE III STUDY COMPARING COMBINED EXTERNAL BEAM
RADIATION AND TRANSPERINEAL INTERSTITIAL PERMANENT BRACHYTHERAPY
WITH BRACHYTHERAPY ALONE FOR SELECTED PATIENTS WITH INTERMEDIATE
RISK PROSTATIC CARCINOMA |
NSABP B-39/
RTOG 0413
|
A RANDOMIZED PHASE III STUDY
OF CONVENTIONAL WHOLE BREAST IRRADIATION (WBI)
VERSUS PARTIAL BREAST IRRADIATION (PBI)
FOR WOMEN WITH STAGE 0, I, OR II BREAST CANCER |
|
A PHASE III RANDOMIZED STUDY OF HYPOFRACTIONATED
3D-CRT/IMRT VERSUS CONVENTIONALLY FRACTIONATED
3D-CRT/IMRT IN PATIENTS WITH FAVORABLE-RISK PROSTATE CANCER
|
|
A PHASE II STUDY OF AN ORAL EPIDERMAL GROWTH FACTOR
RECEPTOR TYROSINE KINASE INHIBITOR (EGFR TKI) ZD 1839
(IRESSA(r)) IN COMBINATION WITH
DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY
IN UNTREATED PATIENTS WITH LOCALLY ADVANCED
CERVICAL CARCINOMA
|
|
A PHASE II STUDY OF INTENSITY MODULATED RADIATION
THERAPY (IMRT) TO THE PELVIS +/- CHEMOTHERAPY FOR
POST-OPERATIVE PATIENTS WITH EITHER ENDOMETRIAL OR
CERVICAL CARCINOMA
|
|
A RANDOMIZED, PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF PALIFERMIN (NSC# 740548; IND #6370)
FOR THE REDUCTION OF ORAL MUCOSITIS IN PATIENTS WITH LOCALLY ADVANCED
HEAD AND NECK CANCER RECEIVING RADIATION THERAPY WITH CONCURRENT CHEMOTHERAPY (FOLLOWED BY SURGERY FOR SELECTED PATIENTS)
|
|
A PHASE III TRIAL EVALUATING THE ADDITION OF CETUXIMAB TO
PACLITAXEL, CISPLATIN, AND RADIATION FOR PATIENTS WITH
ESOPHAGEAL CANCER WHO ARE TREATED WITHOUT SURGERY
|
|
A PHASE I TRIAL OF HIGHLY CONFORMAL
RADIATION THERAPY FOR PATIENTS WITH LIVER METASTASES
|
|
A PHASE III PROTOCOL OF ANDROGEN SUPPRESSION (AS) AND
3DCRT/IMRT VS. AS AND 3DCRT/IMRT FOLLOWED BY
CHEMOTHERAPY WITH DOCETAXEL AND PREDNISONE
FOR LOCALIZED, HIGH-RISK PROSTATE CANCER
|
|
A RANDOMIZED PHASE III TRIAL OF CONCURRENT ACCELERATED
RADIATION AND CISPLATIN VERSUS CONCURRENT ACCELERATED
RADIATION, CISPLATIN, AND CETUXIMAB (C225)
[FOLLOWED BY SURGERY FOR SELECTED PATIENTS]
FOR STAGE III AND IV HEAD AND NECK CARCINOMAS
|
|
A PROSPECTIVE PHASE II TRIAL OF TRANSPERINEAL
ULTRASOUND-GUIDED BRACHYTHERAPY FOR LOCALLY RECURRENT
PROSTATE ADENOCARCINOMA FOLLOWING EXTERNAL BEAM
RADIOTHERAPY
|
|
A PHASE III TRIAL OF SHORT TERM ANDROGEN DEPRIVATION WITH
PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPORT)
IN PROSTATE CANCER PATIENTS WITH A RISING PSA AFTER RADICAL
PROSTATECTOMY
|
|
A PHASE II STUDY OF CONCURRENT CHEMORADIOTHERAPY USING THREE-DIMENSIONAl
CONFORMAL RADIOTHERAPY (3D CRT) OR INTENSITY-MODULATED RADIATION ThERAPY
(IMRT) + BEVACIZUMAB (BV) FOR LOCALLY OR REGIONALLY ADVANCED NASOPHARYNGEAL CANCER
|
|
A PHASE I/II DOSE INTENSIFICATION STUDY USING THREE DIMENSIONAL CONFORMAL
RADIATION THERAPY AND CONCURRENT CHEMOTHERAPY FOR PATIENTS WITH INOPERABLE,
NON-SMALL CELL LUNG CANCER |
|
A PHASE II TRIAL OF STEREOTACTIC BODY RADIATION THERAPY (SBRT)
IN THE TREATMENT OF PATIENTS WITH OPERABLE STAGE I/II
NON-SMALL CELL LUNG CANCER
|
|
ADJUVANT 3DCRT/IMRT IN COMBINATION WITH ANDROGEN SUPPRESSION
AND DOCETAXEL FOR HIGH RISK PROSTATE CANCER PATIENTS
POST-PROSTATECTOMY: A PHASE II TRIAL
|
|
A PHASE I/II TRIAL OF SAMARIUM-153 FOLLOWED BY SALVAGE PROSTATIC FOSSA
IRRADIATION IN HIGH-RISK, CLINICALLY NON-METASTATIC PROSTATE CANCER
AFTER RADICAL PROSTATECTOMY
|
|
A PHASE II TRIAL OF COMBINED MODALITY THERAPY WITH GROWTH FACTOR
SUPPORT FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER
|
|
A PHASE II TRIAL OF IMAGE GUIDED PREOPERATIVE RADIOTHERAPY
FOR PRIMARY SOFT TISSUE SARCOMAS OF THE EXTREMITY
|
|
A PHASE II EVALUATION OF PREOPERATIVE CHEMORADIOTHERAPY
UTILIZING INTENSITY MODULATED RADIATION THERAPY (IMRT)
IN COMBINATION WITH CAPECITABINE AND OXALIPLATIN FOR
PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
|
|
|
